Cohort Study on Biomarkers and Clinical Treatment of Tinnitus

Sponsor
Zhiwu Huang, Ph.D. (Other)
Overall Status
Recruiting
CT.gov ID
NCT05871294
Collaborator
(none)
40
1
2
22
1.8

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to search for biomarkers in tinnitus patients in tinnitus patients and changes in biomarkers before and after treatment. The main questions it aims to answer are:

  • What are the biomarkers of tinnitus patients?

  • How do these biomarkers change during treatment and is there a good correlation with behavioral outcomes? Participants will be asked to complete audiological examination, tinnitus assessment, and magnetoencephalography examination, and they will receive sound therapy or repetitive transcranial magnetic stimulation therapy.

Condition or Disease Intervention/Treatment Phase
  • Device: Acoustic stimulation
  • Device: Repetitive transcranial magnetic stimulation
N/A

Detailed Description

This study aims to use magnetoencephalography (MEG) to collect the resting state responses before and after treatment in the control group, tinnitus patients in the acoustic stimulation treatment group, and rTMS treatment group. Firstly, compare the differences in power spectrum and brain functional connectivity indicators between tinnitus patients and normal control groups in different frequency bands, providing a theoretical basis for clinical diagnosis, precise positioning of tinnitus damaged areas, and understanding the pathogenesis of tinnitus; Secondly, compare the electrophysiological functional indicators of tinnitus patients before and after treatment to reveal whether the damaged brain network can gradually reshape after treatment, and whether network information can serve as potential biomarkers to indicate the degree of tinnitus recovery; Finally, compare the effectiveness differences between the two treatment methods, analyze their influencing factors, and provide guidance for frequency band precise intervention and rehabilitation of chronic tinnitus patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Cohort Study on Biomarkers and Clinical Treatment of Tinnitus
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acoustic stimulation therapy

Patients in this group will receive acoustic stimulation therapy.

Device: Acoustic stimulation
The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.

Experimental: Repetitive transcranial magnetic stimulation therapy

Patients in this group will receive repetitive transcranial magnetic stimulation therapy.

Device: Repetitive transcranial magnetic stimulation
The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)

Outcome Measures

Primary Outcome Measures

  1. THI [Baseline]

    the scores of tinnitus handicap inventory(0-100)

  2. THI [within 7 days of treatment completion]

    the scores of tinnitus handicap inventory(0-100)

  3. THI [follow-up for 1 month after treatment completion]

    the scores of tinnitus handicap inventory(0-100)

  4. VAS [Baseline]

    Visual Analog Scale (VAS) is used to evaluate the loudness of tinnitus. The score range is 0-10

  5. VAS [within 7 days of treatment completion]

    Visual Analog Scale (VAS) is used to evaluate the loudness of tinnitus. The score range is 0-10

  6. VAS [follow-up for 1 month after treatment completion]

    Visual Analog Scale (VAS) is used to evaluate the loudness of tinnitus. The score range is 0-10

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Subjective tinnitus lasting for more than 6 months, with a score of>36 of the Tinnitus Disability Inventory (THI);

  2. The otoscopy examination showed that the ear canal and eardrum were normal, and the tympanic impedance maps of both ears were Type A, indicating that language ability met the requirements of language testing

Exclusion Criteria:
  1. Family or congenital deafness history, ototoxicity drug use history, otitis media patients, etc

  2. Suffering from major physical diseases (sensory and motor disorders, neurological disorders, brain injuries, and other organic diseases) or mental disorders

  3. The patient has aggressive behavior and an impulse to damage the device

  4. Metal in the body (including orthodontics, dental implants), tattoos, and heart stent surgery

  5. Having claustrophobia

  6. Contraindications to magnetic resonance examination

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Shanghai Shanghai China 200000

Sponsors and Collaborators

  • Zhiwu Huang, Ph.D.

Investigators

  • Principal Investigator: Zhiwu Huang, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zhiwu Huang, Ph.D., Professor, PHD, Director of the Hearing Center, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
ClinicalTrials.gov Identifier:
NCT05871294
Other Study ID Numbers:
  • SH9H-2022-T379-1
First Posted:
May 23, 2023
Last Update Posted:
May 23, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 23, 2023